Table 1.

Characteristics of included trials

Characteristics	Number	Percentage
Journal
NEJM	16	11.3
Lancet	6	4.2
JAMA	8	5.6
JAMA Internal Medicine	1	0.7
European Heart Journal	20	14.1
Circulation	14	9.9
JACC	9	6.3
JAMA Cardiology	1	0.7
JACC Clinical Electrophysiology	7	4.9
Circulation Arrhythmia and Electrophysiology	21	14.8
Heart Rhythm	15	10.6
Europace	18	12.7
Journal of Cardiovascular Electrophysiology	6	4.2
Journal category
General Medicine	31	21.8
General cardiology	44	40.0
Cardiac Electrophysiology	67	47.2
Year of publication
2011–2013	27	19.0
2014–2015	34	23.9
2016–2017	24	16.9
2018–2019	27	19.0
2020–2021	30	21.1
Sample size
Less than 250	81	57.0
250 to 750	37	26.1
More than 750	24	16.9
Centers
Multicenter	102	71.8
Single center	40	28.2
Multinational
Yes	58	40.8
No	84	59.2
Region
Asia Pacific	26	18.3
Europe	44	31.0
North America	25	17.6
South America	1	0.7
Multiregional	46	32.4
Intervention
Catheter ablation	70	49.3
Electrical cardioversion	3	2.1
Surgical ablation	2	1.4
Adjuvant to catheter ablation or electrical cardioversion	18	12.7
Periprocedural oral anticoagulation	14	9.9
Long‐term oral anticoagulation	11	7.7
Left atrial appendage occlusion	4	2.8
Antiarrhythmic drugs	4	2.8
RFM/integrated care	11	7.7
Others	5	3.5
Industry involvement
Yes	66	46.5
No	76	53.5
Female(s) in trial leadership role
Yes	19	13.4
No	123	86.6

Abbreviation: RFM, risk factor management.